Nine analysts have recently rated Illumina (NASDAQ:ILMN), with a mix of bullish to bearish sentiments. The average 12-month price target is now $168.11, a 13.79% decrease from the previous $195.00 target. Analysts from firms like RBC Capital, Guggenheim, and B of A Securities have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Illumina specializes in genetic analysis tools and services, with the majority of its revenue from sequencing. Despite positive revenue growth, the company's market capitalization, net margin, ROE, and ROA are below industry benchmarks, although it has a healthy debt-to-equity ratio.